Superpower peptides available for pre-order. Get first access.

Peptide science

What is AICAR (acadesine)?

AICAR (acadesine) is a nucleoside analog, not a peptide, that activates AMPK. See what its human trials found, why it failed, and why WADA bans it.

Quick answer

AICAR (acadesine) is a nucleoside analog, not a peptide, that activates AMPK. The World Anti-Doping Agency has prohibited it since 2009, and it has no FDA-approved indication as of November 2026. Human trials covered bypass surgery and leukemia, and the 3,080-patient RED-CABG Phase 3 trial stopped for futility. No completed human trial has tested athletic performance.

Published
April 18, 2026
Last updated
November 12, 2026

Key takeaways

  • Regulatory status: AICAR has no FDA-approved indication as of November 2026, and its Phase 3 trial stopped for futility1.
  • Research stage: Human trials covered cardiac surgery and leukemia, and nothing has matched what training does2.
  • Availability: AICAR is not available by prescription or from Superpower, and online material is uncontrolled.
  • Prescribing information: No FDA label exists, only a public record for acadesine3.
  • How it works: AICAR becomes ZMP inside cells, an AMP mimic4 that switches on AMPK.
  • What the research shows: Mice given AICAR daily for four weeks ran 44% farther5 than untreated mice.

What is AICAR?

AICAR stands for 5-aminoimidazole-4-carboxamide ribonucleoside, also called acadesine, a nucleoside analog3 structurally related to adenosine6 rather than a peptide. Inside cells, AICAR switches on the enzyme AMPK.

AICAR was developed as a heart-protection drug7 for coronary artery bypass graft (CABG) surgery. Older papers call the same compound AICA-riboside.

Researchers keep returning to AICAR for the enzyme it switches on.

AICAR activates AMPK by mimicking AMP inside cells

Cells take AICAR up and phosphorylate it to ZMP, a molecule that mimics AMP and activates AMPK8 without the cell's energy stores actually falling.

AMPK is the enzyme cells use to sense a falling energy supply9. Switching it on shifts cells toward burning fuel rather than building new molecules. Obese rats injected with AICAR daily for seven weeks had lower triglycerides and lower blood pressure10.

A growing number of AICAR's cellular effects turn out not to run through AMPK11, so the mechanism does not predict what happens in people.

Human trials of AICAR tested heart protection, not performance

Human trials of AICAR tested heart protection during bypass surgery and therapy for chronic lymphocytic leukemia and other blood cancers, and neither program reached approval.

The leukemia program started in the laboratory, where acadesine killed B-cell leukemia cells in patient samples12. Later work found that the killing did not depend on AMPK13.

ProgramYearParticipantsDesignResultOutcome
Acadesine during bypass surgery71994116Multicenter randomized placebo-controlled trialNo significant difference in ischemia endpoints, mild rise in uric acid at the higher doseProgram continued
Pooled analysis of 5 bypass trials1419974,043Patient-level meta-analysis of randomized placebo-controlled trials27% fewer perioperative myocardial infarctions, transient rise in uric acidSupported a confirmatory trial
Survival after perioperative infarction152006100Post-hoc subgroup within a 2,698-patient randomized trial2-year mortality 27.8% with placebo versus 6.5% with acadesineHypothesis-generating, not confirmatory
RED-CABG1620123,080 of a planned 7,5001Randomized double-blind placebo-controlled Phase 3 trial, stopped for futilityPrimary composite 5.1% with acadesine versus 5.0% with placebo1Cardiac development ended
Acadesine in relapsed leukemia17201324Open-label Phase I/II dose-ranging studyVariable reductions in circulating leukemia cells, maximum tolerated dose 210 mg/kg17No further development

Short AICAR infusions in healthy men raised muscle glucose uptake modestly, without measurable AMPK activation18. That gap also separates AICAR from metformin, another AMPK activator and the most prescribed glucose-lowering medicine worldwide19.

AICAR activates AMPK directly while metformin acts indirectly

AICAR activates AMPK directly, delivering an AMP mimic without disturbing the cell's energy supply20. Metformin arrives at the same enzyme from the other direction, activating AMPK in liver cells21 after interfering with mitochondrial energy production.

Those mitochondrial effects appear at concentrations higher than clinical doses produce, and the mechanism remains debated22. In cultured muscle cells, AICAR and metformin both needed AMPK to raise glucose transport23.

Other compounds aimed at the same exercise biology, including SLU-PP-332 and MOTS-c, work by different mechanisms and carry their own open safety questions.

AICAR's side effects in trials centered on uric acid

A rise in uric acid17 was the most consistent adverse effect in AICAR's human trials. Human infusion studies also recorded lower blood glucose and infusion-related circulatory effects.

AICAR's human trials all gave the compound by intravenous infusion, which in healthy volunteers raised heart rate and lowered blood pressure24.

In laboratory work AICAR also blocks the cell cycle outside AMPK25. In cell experiments, nucleosides such as adenosine can block AICAR's effect on AMPK26, which makes its behavior hard to predict.

People who should not use AICAR

AICAR's known effects make it a poor fit for several groups. No use outside an approved research study has an established safety basis.

WADA prohibits AICAR at all times

AICAR is prohibited at all times under category S4.4.1, activators of AMP-activated protein kinase28, within class S4, hormone and metabolic modulators. The prohibition applies in-competition and out-of-competition. Athletes should check the current rules of their own governing body.

AICAR joined the list in 2009, after mouse endurance findings29 drew attention to it.

People make AICAR naturally and excrete it in urine30, so concentration alone cannot prove use. Laboratories tell administered AICAR from the body's own with carbon isotope measurements31 and a urinary ratio that triggers confirmation32. Anti-doping rules are the only place AICAR holds a settled regulatory status.

AICAR has no approval and no active development program

As of November 2026, AICAR has no FDA-approved indication and no publicly registered active development program. AMPK itself remains a live drug target, and few direct activators have reached clinical trials33. Each was designed for the specificity AICAR never had.

Where can I learn about peptides?

AICAR sits beside peptides in search results and supplement forums, although it belongs to a different chemical family. A team of health journalists and licensed clinicians writes and fact-checks Superpower’s peptide library, compound by compound.

AMPK, ZMP, and cellular energy sensing are the kind of biology peptide research borrows from constantly. The science behind peptides covers how these molecules are built, what they target, and what their evidence actually shows.

Important safety information

AICAR (acadesine) is not FDA-approved for any indication. Superpower Health does not prescribe, sell, compound, or facilitate access to AICAR. This article is provided for educational and informational purposes only and does not constitute medical advice. Any use of AICAR outside of an approved clinical trial is investigational and lacks established safety data in the context of fitness, metabolic optimization, or endurance enhancement.

AICAR should not be used by anyone outside an IRB-approved clinical research study. Mechanistic and trial-derived concerns of particular relevance: history of hyperuricemia or gout (AICAR metabolism increases uric acid burden); predisposition to hypoglycemia, including fasted or insulin-sensitive individuals (AICAR-driven AMPK activation increases GLUT4-mediated glucose uptake); known hypersensitivity to adenosine analogs or nucleoside compounds; pregnancy or breastfeeding (no reproductive/developmental data); competitive athletes (WADA category S4.4.1).

Warnings: long-term human safety data do not exist for fitness-relevant doses or durations; off-target cell cycle effects have been identified in preclinical models; endogenous nucleosides may block AICAR-stimulated AMPK activation, creating unpredictable pharmacodynamics; gray-market material sold as a research chemical is uncontrolled for purity, sterility, or dose accuracy.

Common adverse events from clinical trials: hyperuricemia; hypoglycemia risk; infusion-related hypotension.

Anti-doping status: As of the 2026 WADA Prohibited List, AICAR is classified as a prohibited substance under S4.4.1 (activators of AMP-activated protein kinase, within class S4, Hormone and Metabolic Modulators), prohibited both in-competition and out-of-competition. Athletes subject to WADA jurisdiction should be aware that detectable exogenous AICAR constitutes a doping violation regardless of source or intent.

As of November 2026, no active IND for AICAR in metabolic, endurance, or performance indications is publicly registered. No completed human efficacy trials for fitness applications have been published. Full FDA-approved prescribing information does not exist; compound reference data available at PubChem (CID 17513)3.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to AICAR. AICAR is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

More peptide science